Quick Answer
Aptevo Therapeutics Inc. reported Research And Development Expense of $14.54 million for the year ending 2025.
- Aptevo Therapeutics Inc. showed an increase of +1.1% in Research And Development Expense from 2024 to 2025.
- This data is from Aptevo Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $7.71 million | Q1 2016: $8.10 million | Q2 2016: $7.64 million | Q3 2016: $7.08 million | Q1 2017: $5.87 million | Q2 2017: $6.79 million | Q3 2017: $7.18 million | Q1 2018: $8.20 million | Q2 2018: $9.71 million | Q3 2018: $8.57 million | Q1 2019: $6.63 million | Q2 2019: $6.13 million | Q3 2019: $7.60 million | Q1 2020: $4.01 million | Q2 2020: $4.44 million | Q3 2020: $4.49 million | Q1 2021: $5.36 million | Q2 2021: $4.72 million | Q3 2021: $4.37 million | Q1 2022: $4.87 million | Q2 2022: $3.87 million | Q3 2022: $4.48 million | Q1 2023: $4.17 million | Q2 2023: $5.46 million | Q3 2023: $3.89 million | Q1 2024: $3.75 million | Q2 2024: $3.64 million | Q3 2024: $3.10 million | Q1 2025: $3.63 million | Q2 2025: $3.33 million | Q3 2025: $4.04 million.
- Over the full 11 years of available data (2015 to 2025), Aptevo Therapeutics Inc.'s Research And Development Expense has declined by 58.1%.
- Historical annual values: Fiscal year 2025: $14.54 million | Fiscal year 2024: $14.38 million | Fiscal year 2023: $17.11 million | Fiscal year 2022: $17.88 million | Fiscal year 2021: $18.99 million | Fiscal year 2020: $17.85 million | Fiscal year 2019: $24.76 million | Fiscal year 2018: $35.39 million | Fiscal year 2017: $29.02 million | Fiscal year 2016: $29.12 million | Fiscal year 2015: $34.73 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: